IDH1 and central nervous system cancer: Our study confirms that liquid biopsy and cfDNA could be a complementary methods to tissue biopsy in the detection of IDH1 mutation, which can be used as a strong prognostic and predictive biomarker for a favorable clinical outcome in patients with glioma.